Diabetes Studies

Effect of Food Composition on Postprandial Insulin Secretion in Neonatal Diabetes (1701366)

Neonatal diabetes is diagnosed before 6 months of age and causes high blood glucose levels due to the pancreas not secreting insulin. Neonatal diabetes can be caused by a change in a DNA region called the KCNJ11 gene. KCNJ11 encodes a channel in the pancreas that acts as a switch to turn ‘on’ and ‘off’ insulin secretion. A change in KCNJ11 results in a faulty channel, which keeps insulin secretion ‘switched off’. The diabetes can be treated with tablets called sulphonylureas that switch the pancreatic channel ‘on’, allowing it to secrete insulin in response to gut hormones called incretins.

Study of IMCY-0098 in Patients With Recent Onset Type 1 Diabetes (1712543)

A Phase I Placebo-controlled, Double-blind, Dose Escalation Clinical Trial to Evaluate the Safety and Immune Responses of Imcyse’s IMCY-0098 in Patients With Recent Onset Type 1 Diabetes.

The Effects of BAY1193397 on Skin Capillary Blood Flow and Transcutaneous Oxygen Pressure (1608298)

A randomized, single blind, threefold crossover, single center study to assess the safety and the effects of 1 mg and 5 mg BAY 1193397 in comparison to placebo on skin capillary blood flow and transcutaneous oxygen pressure after single dose in type II diabetic patients with peripheral artery disease.

for Adipose Tissue DIabetes VAriants (fATDIVA) (1508127)

The adipose (fat) cells under the skin are where individuals store excess fat. The more excess fat they have, the more “strain” they put on these cells which then get bigger and don’t work as well as they should. Having some fat under the skin is important. People who have a genetic defect which results in them having almost no fat under their skin have a very high risk of a condition called insulin resistance (where the body does not respond as well to insulin and blood sugar levels rise). This can lead to diabetes and heart disease despite them not being overweight.

An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry (1403903)

An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Levemir® (Insulin Detemir) in Pregnant Women With Diabetes Mellitus.
 
 
Characterisation of people with new-onset type 1 diabetes (<6 months duration) and their siblings who are free from diabetes. Participants consent to be contacted about other type 1 diabetes research.
 
 
Type I diabetes occurs when an individual loses the ability to make enough insulin to control their blood sugar levels.  They need insulin injections to replace the insulin production that has been lost. Traditionally people with T1D are thought to make none of their own insulin after diagnosis, but we have recently identified that there are some people who have T1D but go one making insulin for many years. We would like to explore this in more depth and understand why some people with T1D go on making insulin and some do not. This will help us understand the causes of T1D and may help work out ways to protect this remaining insulin production, with improved blood sugar control, and reduced long term complications of diabetes.
 
Type 2 Diabetes is a common health condition where the sufferer has difficulty controlling their blood sugar (glucose) as they do not produce enough insulin to function properly (insulin deficiency), or that the body’s cells don’t react to insulin as they should do (insulin resistance). Over 4% of the population has Type 2 diabetes. It is a major cause of illness and accounts for around 10% of the money spent in the NHS. Good control of blood sugar with appropriate life style and medication makes patients feel better and reduces the risks of complications of diabetes.
 
The current guidelines for treatment of patients with Type 2 diabetes list a large number of drugs without giving clear guidance on which patients should have which drugs. This makes it difficult for patients and their health care professionals to know which drugs are likely to suit them best. In type 2 diabetes.
 
 
This is a proof of concept randomized controlled trial in which overweight/obese females will be randomised to a dietary weight loss intervention (ADF or CR) to achieve ≥5% WL. Behavioural measures of appetite control including ad libitum intake after a fixed meal, body composition, resting metabolic rate, measured physical activity and daily energy expenditure, sleep quality, energy balance regulating hormones, hedonic food reward and eating behaviour traits will be assessed before, during and after the WL intervention in those who reach the target weight loss within 12 weeks.
 
After weight loss phase, participants will be given standard healthy eating and physical activity advice for weight maintenance and body weight will be followed up after weight loss at 3 months, 6 months and 12 months.
Studying people with very early-onset diabetes will enable us to look at exactly what goes wrong with the immune system because they have one of the most extreme forms of the disease. We may be able to learn a lot about the disease from a small number of rare individuals. We aim to confirm that they have autoimmune type 1 diabetes and then try to understand how it is possible that they have developed diabetes so young by studying their immune system genes, the function of their immune system, and environmental factors (such as maternal genetics) that may play a role in their development of the disease.
The aim of this trial is to assess the effectiveness of intermediate care clinics for diabetes, compared to usual care.